Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Dacomitinib for the treatment of advanced or metastatic non-small-cell lung cancer.

Future oncology (London, England) - 1 Apr 2014

Mok Tony, Lee Kirsty, Tang Michael, Leung Linda

Abstract excerpt

Dacomitinib (PF-00299804) is a second-generation irreversible HER tyrosine kinase inhibitor (TKI). In preclinical studies, dacomitinib has demonstrated anti-tumor activity in lung cancer cell lines with sensitive and resistant EGFR mutations (including the T790 mutation). Safety and well tolerability of dacomitinib were demonstrated in Phase I studies with stomatitis, diarrhea and skin toxicities being the...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Clinical Trials as Topic
Share to Drug-Related Side Effects and Adverse Reactions

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Maximum Tolerated Dose

Share to Neoplasm Metastasis

Share to Neoplasm Staging

Share to Protein Kinase Inhibitors

Share to Protein-Tyrosine Kinases

Share to Quinazolinones

Source

Identifiers

PMID: 24799062
DOI: 10.2217/fon.14.22

Genes

EGFR

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 5 Sept 2026. Manifest publication-graph-cohort-2026-09-05.1.

Source receipt: pubmed, retrieved 5 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Dacomitinib for the treatment of advanced or metastatic non-small-cell lung cancer.PMID 24799062Read ↗

Dacomitinib, a new therapy for the treatment of non-small cell lung cancer.Semantic proximity Read ↗

A phase 2 trial of dacomitinib (PF-00299804), an oral, irreversible pan-HER (human epidermal growth factor receptor) inhibitor, in patients with advanced non-small cell lung cancer after failure of prior chemotherapy and erlotinib.Semantic proximity Read ↗

Dacomitinib as first-line treatment in patients with clinically or molecularly selected advanced non-small-cell lung cancer: a multicentre, open-label, phase 2 trial.Semantic proximity Read ↗

Is there a role for dacomitinib, a second-generation irreversible inhibitor of the epidermal-growth factor receptor tyrosine kinase, in advanced non-small cell lung cancer?Semantic proximity Read ↗

Dacomitinib versus gefitinib as first-line treatment for patients with EGFR-mutation-positive non-small-cell lung cancer (ARCHER 1050): a randomised, open-label, phase 3 trial.Semantic proximity Read ↗

Safety and efficacy of first-line dacomitinib in Asian patients with EGFR mutation-positive non-small cell lung cancer: Results from a randomized, open-label, phase 3 trial (ARCHER 1050).Semantic proximity Read ↗

Safety and efficacy of first-line dacomitinib in Japanese patients with advanced non-small cell lung cancer.Semantic proximity Read ↗

Updated Overall Survival in a Randomized Study Comparing Dacomitinib with Gefitinib as First-Line Treatment in Patients with Advanced Non-Small-Cell Lung Cancer and EGFR-Activating Mutations.Semantic proximity Read ↗

Clinical efficacy of dacomitinib in rechallenge setting for patients with epidermal growth factor receptor mutant non-small cell lung cancer: A multicenter retrospective analysis (TOPGAN2020-02).Semantic proximity Read ↗

Dacomitinib compared with placebo in pretreated patients with advanced or metastatic non-small-cell lung cancer (NCIC CTG BR.26): a double-blind, randomised, phase 3 trial.Semantic proximity Read ↗

Dacomitinib versus erlotinib in patients with EGFR-mutated advanced nonsmall-cell lung cancer (NSCLC): pooled subset analyses from two randomized trials.Semantic proximity Read ↗

Real-world data of dacomitinib as first-line treatment for patients with EGFR-mutant non-small-cell lung cancer.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.